• Bogdan Moldoveanu, Alessandra Morello Gearhart, Bilal A Jalil, Mohamed Saad, and Juan J Guardiola.
• Division of Pulmonary, Critical Care, and Sleep Disorders Medicine - Department of Medicine, University of Louisville, Pulmonary, Critical Care and Sleep Division, Louisville, KY, USA. Electronic address: bogdan.moldoveanu@louisville.edu.
• Am. J. Med. Sci. 2021 Apr 1; 361 (4): 411-419.

AbstractAspergillus species are ubiquitous in the environment. Aspergillosis is acquired by inhalation of Aspergillus spores. In normal hosts, spore inhalation rarely causes lung disease. Pulmonary Aspergillosis covers a wide spectrum of clinical syndromes depending on the interaction between Aspergillus and the host (immune-status, prior bronchopulmonary disease). It runs the gamut from invasive Aspergillosis to Aspergillus bronchitis. Invasive Aspergillosis usually occurs in severely immunocompromised patients, typically in neutropenic but also in non-neutropenic patients. Chronic pulmonary Aspergillosis affects patients with chronic structural lung disease such as COPD or previous mycobacterial lung disease, but without other significant immunocompromise. Aspergillus bronchitis affects patients with bronchial disease such as bronchiectasis. Allergic bronchopulmonary Aspergillosis affects patients with bronchial asthma or cystic fibrosis, and is due to an allergic response to Aspergillus.Copyright © 2021. Published by Elsevier Inc.

8 keywords...

hide…